NEW YORK, Oct 27, 2014 (BUSINESS WIRE) — Pfizer Inc. (NYSE:PFE) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc.
Pfizer has concluded an internal review (more…)
CAMBRIDGE, England–(BUSINESS WIRE)–Mundipharma today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Targin®, a fixed combination of prolonged-release oxycodone/naloxone, as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy.1
The positive opinion adopted by the CHMP (more…)
More than 50 people have been charged in a massive prescription painkiller trafficking conspiracy after a year-long investigation by federal, state and local law enforcement agencies.
Most of the defendants were alleged “runners,” paid by forgers to fill 196 fraudulent prescriptions for oxycodone to pharmacies all over the Milwaukee area — 10 counties in all — and obtain 25,000 pills worth about (more…)